Redeye remains positive to Bredband2 despite its soft Q1 margins driven by growth efforts. We make mixed estimate changes for the coming years, seeing a negative temporary margin impact in 2025, while growth stands centered. For 2026 we make positive adjustments, expecting investments to materialize and margins to be back on balance.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/